Interview
with Neil Love, MD from Breast Cancer Update for Surgeons,
Program 1 2000
Play
Audio Below:
It’s
not clear that the same type of person who benefits from tamoxifen
will benefit from raloxifene. They very well might and probably
they will, but the study is being done to clarify this and to find
out what is right now the preferable agent. So the idea that raloxifene
is the ideal intervention for postmenopausal women today, I think
is offered prematurely. We don’t know what the ideal agent
will be, and we don’t know what the long-term effects of raloxifene
in this setting of high-risk women will be. So while it may be less
dangerous for the uterus, it may or may not be as effective for
breast cancer prevention and it should not be thought of as an ideal
treatment that you should give every woman.
Dr.
Love: Should it be given to any woman who is high risk for breast
cancer?
Dr.
Margolese: I wouldn’t give it to anyone for high risk for breast
cancer because tamoxifen is the proven effective agent to inhibit
breast cancer. Raloxifene seems to have activity and even though
the trial showed a substantial reduction in breast cancer, it isn’t
the same group of people in that trial.
It’s
interesting that many physicians think that raloxifene is a good
drug for osteoporosis and don’t think of tamoxifen as a good
drug for osteoporosis. But we cut the serious fracture risk in half,
almost in half, in terms of hip and collies fractures in P1.
Chemoprevention
of breast cancer [Review]. Brown, P. H. and Lippman, S. M. (Reprint available from: Lippman
SM Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent 1515
Holcombe Blvd,Box 236 Houston, TX 77030 USA). Breast Cancer Research
& Treatment. 62(1):1-17, 2000 Jul.
Vitamin
A analogue for breast cancer prevention: a grade of F or incomplete?
Response Piantadosi, S. (Reprint available from: Piantadosi S Johns Hopkins
Univ, Sch Med, Johns Hopkins Oncol Ctr 550 N Broadway,Suite 1103
Baltimore, MD 21205 USA).. Journal of the National Cancer Institute.
92(3):274-275, 2000 Feb 2. No abstract
Tamoxifen
for the prevention of breast cancer in the high-risk woman.
Morrow, M. and Jordan, V. C. (Reprint available from: Morrow M 676
N St Clair St,13th Floor, Room 13-104 Chicago, IL 60611 USA).. Annals
of Surgical Oncology. 7(1):67-71, 2000 Jan-Feb. No abstract
